Analytical and Clinical Assessment of Plasma p-Tau217, BD-Tau, p-Tau181 and Aβ42/Aβ40 Assays in Alzheimer’s Disease (AD) Subjects (P10-3.008)
We have evaluated and validated Quanterix assays p-Tau217 (ALZpath), BD-Tau, p-Tau181, and Aβ42/Aβ40 ratio, and the Fujirebio p-Tau217 assay in plasma of AD subjects and healthy controls to characterize the discriminatory and correlative relationships for each assay and between clinical diagnosis groups.
Authors
- John Winslow (ORCID: https://orcid.org/0000-0003-2701-2493)
- Ahmed Chenna (ORCID: https://orcid.org/0000-0001-6201-2494)
- Christos J. Petropoulos (ORCID: https://orcid.org/0000-0001-5496-8090)
- Youssouf Badal
- Brandon Yee
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211350
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00